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ABSTRACT 
Imipenem-resistant Pseudomonas aeruginosa (IRPA) infection is a serious problem in hospitals. Combination therapy 
is an alternative treatment for this infection. In this study, the in vitro activities of amikacin, aztreonam, ceftazidime, 
ciprofloxacin, colistin, imipenem, and piperacillin/tazobactam alone and in various combinations were determined by 
E-test for 38 imipenem-resistant P. aeruginosa isolates obtained from a Thai hospital. Of the 38 IRPA isolates, 9 (24%) 
were low-level IRPA (defined as MICs of imipenem 8-32 µg/mL) and 29 (76%) were high-level IRPA (defined as MICs of 
imipenem >32 µg/mL). The high-level IRPA isolates were susceptible to colistin (90%), piperacillin/tazobactam (72%), 
and amikacin (52%). The low-level IRPA isolates were susceptible to colistin (100%) and all other antimicrobials tested 
(78%-89%). The MIC
50
 value of colistin against both the high-level and low-level IRPA isolates was 1.5 µg/mL. Of all 
the antimicrobial combinations tested, ceftazidime plus ciprofloxacin displayed the highest percentages of synergistic 
effects against IRPA isolates (26%, 10/38 isolates) and a high percentages of synergistic effects against high-level IRPA 
isolates (21, 6/29 isolates), with no antagonistic effects detected. Colistin had the greatest activity against most IRPA 
isolates among all of the antimicrobials tested, while ceftazidime plus ciprofloxacin showed promise in treating infections 
caused by IRPA isolates including high-level IRPAs. 
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ABSTRAK
Jangkitan rintangan-imipenem Pseudomonas aeruginosa (IRPA) merupakan masalah yang serius di hospital. Terapi 
gabungan adalah rawatan alternatif bagi jangkitan ini. Dalam kajian ini, aktiviti in vitro amikasin, aztreonam, ceftazidime, 
ciprofloxacin, colistin, imipenem dan piperacillin/tazobactam semata-mata serta pelbagai gabungan ditentukan oleh 
ujian E-38 rintangan-imipenem pencilan P. aeruginosa yang diperoleh daripada sebuah hospital di Thailand. Dalam 
pencilan 38 IRPA, 9 (24%) ialah IRPA tahap rendah (ditakrifkan sebagai MICs imipenem 8-32 µg/mL) dan 29 (76%) IRPA 
tahap tinggi (ditakrifkan sebagai MICs imipenem > 32 µg/mL). Pencilan IRPA tahap tinggi telah menyebabkan ia terdedah 
kepada colistin (90%), piperacillin/tazobactam (72%) dan amikasin (52%). Pencilan IRPA tahap rendah rentan kepada 
colistin (100%) dan semua ujian antimikrob (78% - 89%). Nilai colistin MIC
50
 terhadap kedua-dua pencilan di peringkat 
tinggi dan IRPA tahap rendah adalah 1.5 µg/mL. Daripada semua kombinasi antimikrob yang diuji, ceftazidime dan 
ciprofloxacin menunjukkan peratusan tertinggi kesan bersinergisma terhadap pencilan IRPA (26%, pencilan 10/38) dan 
tinggi peratusan daripada kesan bersinergisma terhadap tahap tinggi IRPA terasing (21%, pencilan 6/29) dengan tiada 
kesan berantagonis dikesan. Colistin menunjukkan aktiviti terbesar berbanding kebanyakan pencilan IRPA antara semua 
antimikrob yang diuji, manakala ceftazidime dan ciprofloxacin menunjukkan keupayaan dalam merawat jangkitan yang 
disebabkan oleh pencilan IRPA termasuk IRPAs tahap tinggi.
Kata kunci: Etest; Pseudomonas aeruginosa; rintangan imipenem; sinergi
INTRODUCTION
Pseudomonas aeruginosa is a nosocomial pathogen and 
cases involving such infections have become a serious 
problem in hospitals, especially in critically ill and 
immunocompromised patients. P. aeruginosa is frequently 
identified as the cause of surgical site infections (18%), 
respiratory tract infections (17%), and bloodstream 
infections (8%) (Lister et al. 2009; Tolera et al. 2018). This 
pathogen can survive in various environments such as in 
variable pH and temperature conditions. P. aeruginosa 
endosymbionts have also been detected in Acanthamoeba 
hosts from dust samples in air-conditioning vents in wards 
and operating theatres (Faizah et al. 2017). P. aeruginosa 
has been found to be resistant to several antipseudomonal 
agents (β-lactams, aminoglycosides, and fluoroquinolones). 
The mechanisms of resistance are associated with 
β-lactamases, decreased bacterial wall permeability, target 
alterations, and efflux pumps (Lister et al. 2009).
 Imipenem is used in the empirical treatment of 
Pseudomonas infections. However, imipenem-resistant 
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strains have been detected during therapy (Kanj & 
Kanafani 2011). In Asian countries, a recent study found 
the resistance rate of P. aeruginosa to imipenem was 
27.2% (Kang & Song 2013). Resistance to imipenem in 
P. aeruginosa can be due to decreased outer membrane 
permeability by loss of the OprD porin, increased efflux 
systems, or metallo- β-lactamases (Laupland et al. 2005; 
Lister et al. 2009). 
 Combination therapy has recently been suggested as 
an alternative for the treatment of severe P. aeruginosa 
infections as it has shown increased bactericidal activity, 
reduced toxicity, and lower rates of resistant strains during 
therapy (Moore & Flaws 2011; Song et al. 2003).
 Previous in vitro studies have reported that combinations 
of antipseudomonal agents such as ceftazidime plus 
amikacin (Song et al. 2003), ceftazidime plus ciprofloxacin 
(Altoparlak et al. 2005), tazobactam/piperacillin plus 
amikacin (Farzana & Shamsuzzaman 2015; Fujimura 
et al. 2009), and amikacin plus imipenem (Farzana & 
Shamsuzzaman 2015) have shown good synergistic effects 
against imipenem-resistant P. aeruginosa (IRPA) strains.
The aim of this study was to determine the in vitro activity of 
13 antimicrobial combinations against imipenem-resistant 
P. aeruginosa isolated from patients at Songklanagarind 
Hospital in Southern Thailand.
MATERIALS AND METHODS
BACTERIAL ISOLATES
Thirty-eight IRPA isolates were collected from clinical 
samples such as sputum (27), pus (4), body fluid (3), 
tissue (3) and blood (1) from patients at Songklanagarind 
Hospital in Songkhla Province, Thailand during the 
July 2012-October 2013 period. The bacterial isolation 
and identification were performed using standard 
laboratory methods (Giligan 1995). Imipenem-resistant 
P. aeruginosa (IRPA) was defined as an isolate confirmed 
to be resistant to imipenem. MICs of 8-32 µg/mL were 
considered as low-level resistance, and MICs greater 
than 32 µg/mL were considered as high-level resistance 
(Patzer & Dzierzanowska 2007). The Ethics Committee 
of the Faculty of Medicine, Prince of Songkla University 
approved the study (REC 58-268-01-8). 
ANTIMICROBIAL SUSCEPTIBILITY TESTING                             
AND MIC DETERMINATION
The antimicrobial susceptibilities and minimal inhibitory 
concentrations (MICs) of amikacin (0.016-256 µg/mL, 
AK), aztreonam (0.016-256 µg/mL, ATM), ceftazidime 
(0.016-256 µg/mL, CAZ), ciprofloxacin (0.002-32 µg/mL, 
CIP), colistin (0.016-256 µg/mL, CS), imipenem (0.002-
32 µg/mL, IMI), and piperacillin/tazobactam (0.016-256 
µg/mL, TZP) (Liofilchem, Roseto degli Abruzzi, Italy) 
were determined using the E-test. The antimicrobial 
susceptibility and MIC breakpoints for P. aeruginosa 
followed the Clinical and Laboratory Standards Institute 
(CLSI) guidelines CLSI 2014). P. aeruginosa ATCC 27853 
was used as the control strain. 
ANTIMICROBIAL COMBINATION TESTING
The antimicrobial combination testing was performed 
following the E-test method (Sueke et al. 2010) by 
placing E-test strips of the two antimicrobial agents on 
an inoculated Mueller Hinton agar plate at a 90° angle 
intersecting at the respective MICs for the organism. 
The plates were incubated at 35oC to 37oC for 18 h. The 
inhibition zone of each antimicrobial agent intersecting 
the E-test strip was interpreted as the MIC of the 
combination. The fractional inhibitory concentrations 
(FICs) were calculated by dividing the MIC of drugs A 
and B in combination by the MIC of drugs A and B alone. 
The fractional inhibitory concentration index (FICI) was 
obtained by the sum of the FICs of each drug. FICI values 
of ≤0.5 were considered synergistic, >0.5 to <4.0 no 
interaction, and >4.0 antagonistic (Fujimura et al. 2009). 
RESULTS
SOURCE OF IRPA ISOLATES
We found that the most common sources of IRPA isolates 
were respiratory tract infections such as ventilator 
associated pneumonia, pneumonia, and chronic lung 
disease (74%, 28/38 cases) followed by surgical site 
infections (16%, 6/38 cases), bloodstream infections (8%, 
3/38 cases), and urinary tract infections (3%, 1/38 cases) 
(Data not shown). 
ANTIMICROBIAL SUSCEPTIBILITY TESTING
Of the 38 IRPA isolates, the susceptibility rate was highest 
against colistin, followed by piperacillin/tazobactam, 
amikacin, ciprofloxacin, ceftazidime, and aztreonam. 
The MIC
50
 values of amikacin, colistin, ciprofloxacin, 
and piperacillin/tazobactam were lower than the CLSI 
susceptibility breakpoint (Table1).
 High-level IRPAs were found in 29/38 (76%) of the 
cases. Colistin exhibited excellent activity against the 
majority of high-level IRPA isolates (90% susceptibility 
rates and an MIC
50
 of 1.5 μg/mL). However, colistin-
resistant isolates (having MICs 3 µg/mL) were found in 
3/29 (10%) of the high-level IRPA isolates. Regarding the 
other antimicrobials tested, the high-level IRPA isolates 
showed high rates of susceptibility (52% and 72%) only 
for amikacin and piperacillin/tazobactam (Table 1).
 Low-level IRPAs were found in 9/38 (24%) of the cases. 
Colistin exhibited excellent activity against all low-level 
IRPA isolates (100% susceptibility rates and an MIC
50
 of 
1.5 µg/mL). Regarding all other antimicrobials tested, the 
low-level IRPA isolates exhibited high rates of susceptibility 
(78%-89%) and the MIC
50
 values of all other antimicrobial 
agents were lower than the CLSI susceptibility breakpoint 
(Table 1). 
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ANTIMICROBIAL COMBINATIONS TESTING
Of the 38 IRPA isolates, the top five combinations exhibiting 
high synergistic effects were ceftazidime plus ciprofloxacin 
(26%, 10/38 isolates), imipenem plus aztreonam (18%, 
7/38 isolates), ceftazidime plus amikacin (13%, 5/38 
isolates), imipenem plus ciprofloxacin and piperacillin/
tazobactam plus aztreonam (10%, 4/38 isolates for both 
combinations), and piperacillin/tazobactam plus amikacin 
(5%, 2/38 isolates) - no antagonism was observed in these 
combinations except for imipenem plus aztreonam (29%, 
11/38 isolates) and ceftazidime plus amikacin (3%, 1/38 
isolates). Overall, we observed that all combinations of 
piperacillin/tazobactam with each antimicrobial agent 
showed synergistic effects with no antagonism (Table 2). 
Of the 29 high-level IRPA isolates, the top five combinations 
exhibiting high synergistic effects were imipenem 
plus aztreonam (24%, 7/29 isolates), ceftazidime plus 
ciprofloxacin (21%, 6/29 isolates), ceftazidime plus 
amikacin (17%, 5/29 isolates), piperacillin/tazobactam 
plus aztreonam (14%, 4/29 isolates), and imipenem plus 
ciprofloxacin and piperacillin/tazobactam plus amikacin 
(7%, 2/29 isolates for both combinations) - no antagonism 
was observed in these combinations except for imipenem 
plus aztreonam (10%, 3/29 isolates) and ceftazidime plus 
amikacin (3%, 1/29 isolates). Overall, we observed that 
all combinations of piperacillin/tazobactam with each 
antimicrobial agent presented synergistic effects with no 
antagonism (Table 2). 
 Synergy was observed in none of the three colistin-
resistant isolates. However, antagonism was observed in 
amikacin plus ciprofloxacin, ceftazidime plus amikacin, 
ceftazidime plus aztreonam, and imipenem plus amikacin 
(33%, 1/3 isolates for all combinations) (Data not shown). 
DISCUSSION
In our study, we found that colistin remained the most 
effective antimicrobial agent against IRPA isolates 
(including both the low-level and high-level IRPA isolates) 
- 90%-100% susceptibility rates and MIC
50
s of 1.5 μg/
mL. Previous studies have reported similar data - 95%-
100% of IRPA isolates being susceptible to colistin and 
MIC
50
s of <1.5 μg/mL (Nazli et al. 2015; Sanal et al. 
2016; Tam et al. 2010). Colistin is recommended for the 
treatment of multidrug-resistant P. aeruginosa infections. 
However, the associated adverse effects (nephrotoxicity 
and neurotoxicity) and colistin-resistant strains remain a 
concern (Dalfino et al. 2015; Leung et al. 2008; Memar 
et al. 2016). 
 Our results demonstrated that piperacillin/tazobactam 
and amikacin are effective antimicrobial agents against 
high-level IRPA isolates. However, piperacillin/tazobactam 
and amikacin alone have been associated with a risk of 
selection for resistant strains (Harris et al. 2002; Kanj & 
Kanafani 2011), and amikacin alone is recommended only 
for the treatment of lower urinary tract infections (Kanj & 
Kanafani 2011; Moore & Flaws 2011).
 This study found that amikacin, aztreonam, 
ceftazidime, ciprofloxacin, and piperacillin/tazobactam 
were effective antimicrobial agents against low-level IRPA 
isolates (78%-89% susceptibility rates and low MIC
50
s), 
suggesting that these antimicrobial agents could be 
useful for the treatment of infections due to IRPA isolates, 
when MICs of imipenem are 12-16 μg/mL. Resistance to 
imipenem in P. aeruginosa is mostly mediated by OprD 
loss (Pai et al. 2001). This study found 7 of 9 low-level 
IRPA isolates exhibited only resistance to imipenem. We 
assume the loss of the OprD porin plays an important 
role in the majority of these isolates although we did 
not study the mechanisms of resistance to imipenem 
in these isolates. However, this possibility should be 
further evaluated with a larger number of organisms 
and investigations into the mechanisms of resistance to 
imipenem.
 Our study found that IRPA isolates were the 
predominant pathogens causing respiratory tract 
infections, especially ventilator associated pneumonia. 
A previous study reported that P. aeruginosa ventilator 
associated pneumonia was associated with biofilm 
formation, which lead to persistent or recalcitrant to 
antimicrobial agents. Drugs with an MIC were not 
effective against these isolates. The concentrations of 
antimicrobials required to kill biofilm isolates under 
either in vitro or in vivo conditions can be in excess of 
200 times the MIC (Soboh et al. 1995). These findings are 
in agreement with another study on patients with biofilm 
infections, in which high dosages of antimicrobial agents 
within the safe ranges of renal and hepatic functions were 
suggested (Wu et al. 2015). 
 P. aeruginosa is an opportunistic human pathogen 
commonly found in the environment in soil, water, 
and animals. Because of different intrinsic or acquired 
mechanisms of resistance, P. aeruginosa infections 
are difficult to treat. We found that colistin, amikacin, 
ciprofloxacin, and piperacillin/tazobactam were effective 
antimicrobial agents against the IRPA isolates from our 
hospital. These isolates were resistant to aztreonam and 
ceftazidime. A study by Golle et al. (2017) found a high 
percentage of imipenem-resistant P. aeruginosa isolates 
from clinical (36%, 47/130 isolates) and environmental 
(52%, 32/61 isolates) settings. Their IRPA isolates showed 
high percentages of resistance to piperacillin/tazobactam 
(52%) and ceftazidime (42%) among the clinical isolates 
and ceftazidime (37%) and ciprofloxacin (35%) among 
the environmental isolates. The IRPA isolates from the 
clinical settings showed various antimicrobial resistance 
patterns, including resistance to carbapenems only and 
resistance to all classes of antimicrobials tested, while 
most of the IRPA isolates from environmental settings 
showed predominant resistance to carbapenems only 
and resistance to all classes of antimicrobials tested. The 
data from our results and the study of Golle et al. (2017) 
indicate that IRPA could be ubiquitous in both clinical and 
environmental settings, and antimicrobial resistance is a 
serious concern. 
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 In this study, the synergy rates in combinations 
of β-lactams and aminoglycosides, β-lactams and 
fluoroquinolones, β-lactams and aztreonam, colistin 
and β-lactams or piperacillin/tazobactam, piperacillin/
tazobactam and aminoglycosides or fluoroquinolones or 
aztreonam, and aminoglycosides and fluoroquinolones 
against IRPA isolates were 3%-13%, 10%-26%, 3%-18%, 
0%-3%, 3%-10%, and 0%, respectively.
 Synergy from these combinations has been reported 
in many studies and higher or lower synergy rates for the 
same combinations against IRPA isolates have been found 
by different investigators (Amer & Abd-Elmonsef 2016; 
Dundar & Otkun 2010; Farzana & Shamsuzzaman 2015; 
Sader et al. 2003; Song et al. 2003; Tellis et al. 2016; 
Yasmin et al. 2013). However, the comparison of results 
from different studies is difficult due to variations in 
microbiology tests, methods, and definitions of synergy 
among studies (Sader et al. 2003). Of note, we used the 
e-test method due to it is simple to use in routine clinical 
practice, time-efficient, inexpensive, and has been shown 
to be useful for performing in vitro synergy testing in 
P. aeruginosa and other bacterial species (Pankey & 
Ashcraft 2005; White et al. 1996). 
 Regarding combinations of  β-lactams and 
aminoglycosides, we found that ceftazidime plus 
amikacin exhibited synergy rates against IRPA and 
high-level IRPA isolates of 13%-17% and low levels 
of antagonism (3% for both IRPA and high-level IRPA 
isolates). Previously, Song et al. (2003) found that the 
combination of ceftazidime plus amikacin produced a 
17% rate of synergy against 24 IRPA isolates, with no 
antagonism detected (Song et al. 2003). Likewise, Nazli 
et al. (2015) reported that the synergy rate of ceftazidime 
plus amikacin against 60 P. aeruginosa isolates, of which 
some isolates were resistant to imipenem, was 15%, with 
no antagonism detected in this combination (Nazli et al. 
2015). Thus, ceftazidime plus amikacin could be useful 
in combatting IRPA isolates. However, combining a 3rd or 
4th generation cephalosporin along with amikacin should 
be considered as the first choice of therapy when the 
patient has no other factors predisposing to nephrotoxicity 
(Tellis et al. 2016). Looking at imipenem plus amikacin 
against IRPA isolates, various synergy rates have been 
reported by earlier investigators, with no antagonism 
detected (Farzana & Shamsuzzaman 2015; Nazli et al. 
2015; Song et al. 2003). We found that imipenem plus 
amikacin exhibited less synergy against IRPA and high-
level IRPA isolates (3% for both IRPA and high-level IRPA 
isolates) - antagonism was also discovered in 18% of IRPA 
and 3% of high-level IRPA isolates. In addition, we also 
found that all IRPA isolates in which antagonism effects 
were detected were susceptible to amikacin (MICs of 1.5-
4 µg/mL), which suggests that antagonism may occur 
between two antimicrobial agents although the isolates 
are susceptible to one antimicrobial agent and considering 
that imipenem plus amikacin may not be the most suitable 
choice to treat IRPA infections. In agreement with another 
study, we suspect that antagonism effects in IRPA isolates 
might be influenced by the mechanism of resistance to 
imipenem (Pai et al. 2001); imipenem cannot enhance the 
uptake of amikacin.
 Among the combinations of β-lactams and 
fluoroquinolones evaluated, synergy or indifference 
have generally been detected with antagonism only 
occasionally being reported in small percentages of IRPA 
isolates (Altoparlak et al. 2005; Dundar & Otkun 2010; 
Song et al. 2003; Tellis et al. 2016). A previous study 
by Altoparlak et al. (2005) showed good synergistic 
effects of ceftazidime plus ciprofloxacin against 7 of 21 
(33%) IRPA isolates which were resistant to ceftazidime 
and ciprofloxacin separately (Altoparlak et al. 2005). In 
this study, we found that ceftazidime plus ciprofloxacin 
displayed the highest percentage (26%, 10/38 isolates) 
of synergy against IRPA isolates and a high percentage 
(21%, 6/29 isolates) of synergy against high-level IRPA 
isolates, with no antagonism detected. In addition, we 
also found that 8 of 10 IRPA isolates and 4 of 6 high-level 
IRPA isolates in which synergistic effects were detected 
were susceptible to ceftazidime (MIC ranges of 1.5-4 μg/
mL) and ciprofloxacin (MIC ranges of 0.094-0.75 μg/
mL). The other IRPA isolates were high-level IRPAs (1 of 
2 isolates was resistant to ceftazidime (MIC of 12 μg/mL), 
but was susceptible to ciprofloxacin (MIC of 0.25 μg/mL) 
and 1 of 2 isolates was resistant to both ceftazidime (MIC 
of >256 μg/mL) and ciprofloxacin (MIC of >32 μg/mL). 
These results suggest that ceftazidime plus ciprofloxacin 
could be useful for the treatment of infections due 
to IRPA isolates including high-level IRPAs, although 
the isolate exhibited resistance to ceftazidime and 
ciprofloxacin. Furthermore, we observed that imipenem 
plus ciprofloxacin yielded synergy rates against these 
isolates of high-level IRPAs and IRPA isolates of 7-10% 
with - no antagonism in this combination. Our findings 
indicate that these combinations could be choices for 
IRPA isolates and may be another alternative to replace 
β-lactams plus aminoglycosides, when the physician 
faces limitations due to the toxicity of aminoglycosides 
(Song et al. 2017). In future studies, it will be necessary 
to determine the synergistic effects of ceftazidime plus 
ciprofloxacin against a larger number of IRPA isolates 
resistant to ceftazidime and ciprofloxacin.
 Combinations of piperacillin/tazobactam plus 
either amikacin or ciprofloxacin or aztreonam have 
been reported to show synergistic results (14%-96%) 
against IRPA isolates (Altoparlak et al. 2005; Amer & 
Abd-Elmonsef 2016; Farzana & Shamsuzzaman 2015; 
Fujimura et al. 2009). However, antagonism may 
occur in the combination of piperacillin/tazobactam 
plus ciprofloxacin (Fujimura et al. 2009). In our study, 
we observed that the combinations of piperacillin/
tazobactam plus amikacin or ciprofloxacin or aztreonam 
showed 3-10% synergy against IRPA and 3-14% synergy 
against high-level IRPA isolates, with no antagonism 
detected. Although our results had less synergy in the 
tested combinations against IRPA isolates than other 
investigations, we observed no antagonisms in these 
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combinations. This suggests that piperacillin/tazobactam 
plus amikacin or ciprofloxacin or aztreonam could be 
promising alternatives for fighting IRPA and high-level 
IRPA isolates. For the mechanism of the synergy of these 
combinations, we speculate that piperacillin/tazobactam 
may enhance the uptake of other antimicrobial agents by 
the bacterial cells, because piperacillin inhibits cell wall 
synthesis (Fujimura et al. 2009).
 Although amikacin plus ciprofloxacin has been 
reported to have synergistic or additive effects against 
P. aeruginosa (Gerceker & Gurler 1995; Yasmin et al. 
2013), our study indicates that this combination may 
not be useful for IRPA and high-level IRPA isolates, as we 
observed no synergy with amikacin plus ciprofloxacin in 
all of the IRPA and high-level IRPA isolates tested and we 
also found antagonism in some isolates.
 Aztreonam has been combined with other 
antimicrobial agents, as it has been found to enhance 
the antimicrobial spectrum of co-drugs and yield potential 
synergistic results (Sader et al. 2003). In our study, a 
high synergy potential was found in imipenem plus 
aztreonam when tested against high-level IRPA isolates 
(24%); however, antagonism also occurred in 10% of 
the isolates. Of note, imipenem has been reported to be 
a strong inducer of class I beta-lactamase production 
(Tausk et al. 1985). It is possible that the mechanism of 
the antagonism effect in this combination may have been 
a result of inhibited aztreonam potency by imipenem 
induced beta-lactamase production in the tested isolates 
(Yamaki et al. 1998).
 In our study, the combinations of colistin and 
β-lactams (ceftazidime or imipenem or piperacillin/
tazobactam) exhibited low synergy rates (0-3%) against 
the IRPA and high-level IRPA isolates tested and also 
antagonism was observed in 10% of the colistin plus 
imipenem against IRPA isolates. A recent study on colistin 
plus either ceftazidime or imipenem also reported no 
synergy against IRPA isolates (Nazil et al. 2015), indicating 
that combinations of colistin and β-lactams, especially 
colistin plus imipenem, may not represent potential 
options for IRPA cases - even though another investigation 
found 50% synergy of colistin plus imipenem against 
these isolates (Farzana & Shamsuzzaman 2015). The 
mechanism of colistin in combination with other 
antimicrobials is to increase permeabilization of the 
outer membrane, allowing other antimicrobials to enter 
the bacterial cells (Sanal et al. 2016). We suspect that the 
cause of lower rates of synergy or antagonism in these 
combinations against our isolates may have been a result 
of colistin’s inability to enhance the uptake of β-lactams. 
 A recent study suggested that the increasing use 
of colistin for the treatment of infections caused by 
P. aeruginosa may lead to the emergence of colistin-
resistant strains (Memar et al. 2016). This study was 
based on data from several countries, finding prevalence 
rates of P. aeruginosa resistance to colistin from 2 to 30% 
(Memar et al. 2016). In our study, we found that 8% of 
the IRPA isolates were resistant to colistin. In addition, 
the study of Vidaillac et al. (2012) found that colistin 
with other antimicrobials had no activity against colistin-
resistant strains (Vidaillac et al. 2012). In our study, all 
tested combinations showed no synergy against colistin-
resistant isolates and antagonism also occurred in 33% of 
the isolates for amikacin plus ciprofloxacin, ceftazidime 
plus amikacin, ceftazidime plus aztreonam, and imipenem 
plus amikacin, indicating that these combinations may 
not be an effective option against infections caused 
by colistin-resistant isolates with antagonism effects. 
Of note, a previous study reported colistin-resistant 
P. aeruginosa showed overexpression of the MexAB-
OprM and MexXY-OprM efflux pumps, which are 
associated with cross-resistance to different antimicrobial 
agents including aminoglycosides, β-lactams, and 
fluoroquinolones (Goli et al. 2016). Consequently, it is 
possible that overexpression of these efflux pumps might 
have been associated with an antagonism effect in these 
combinations against our isolates.
 The limitations of this study were the small number of 
isolates, the lack of testing of mechanisms of resistance to 
antimicrobial agents in IRPA isolates, especially acquired 
resistance mechanisms (i.e. mutations in the specific porin 
OprD reduce the uptake of imipenem, the overexpression 
of MexXY-OprM owing to mutations in genes encoding 
mexZ leads to aminoglacoside, fluoroquinolone and 
cefepime resistance in clinical strains of P. aeruginosa, 
and mutations in gyrA and alterations in two efflux 
systems (MexCD-OprJ and MexEF-OprN) leading to 
ciprofloxacin resistance) (Breidenstein et al. 2011), and 
our inability to explain the mechanisms responsible for 
the antimicrobial interactions investigated. Further studies 
investigating these mechanisms with larger numbers of 
isolates are needed to obtain more authoritative data.
CONCLUSION
In summary, among all of the antimicrobials tested, 
we found that colistin had the greatest level of activity 
against most IRPA isolates. Ceftazidime plus ciprofloxacin 
displayed useful properties in treating infections caused 
by IRPA, including high-level IRPA isolates, while 
ceftazidime plus amikacin, imipenem plus ciprofloxacin, 
and combinations of piperacillin/tazobactam plus amikacin 
or aztreonam showed promise as alternative options for 
treatment of IRPA cases. Colistin-resistant isolates were 
detected in 3 (10%) of the high-level IRPAs and all of the 
antimicrobial combinations tested against this isolate 
produced no synergy. Antagonism was found in amikacin 
plus ciprofloxacin, ceftazidime plus amikacin, ceftazidime 
plus aztreonam, and imipenem plus amikacin, thus colistin-
resistant isolates need to be closely monitored. 
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